MindWalk Holdings Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $65.3M
- Price
- $1.39
- % Change (Daily % change from the live per-ticker quote feed.)
- -6.08%
- Volume
- 229.9K
About
MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
Quick stats
Shares outstanding47.0M
Computed float42.4M
Float / shares90.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001715925
Websitehttps://www.mindwalkai.com
AI Summary
AI-generated1/30
minorbullishoperations update
MindWalk Brings OpenFold3 into Production in Minutes with AMD Inference Microservices on Vultr Kubernetes Engine
MindWalk (NASDAQ: HYFT) deployed the open-source OpenFold3 structure prediction model into production on Vultr Kubernetes Engine, powered by AMD Instinct MI325X GPUs and delivered through AMD Inference Microservices, in work run jointly with engineering partners AMD and Vultr.
Antibody-antigen inference ran approximately 5x faster than in MindWalk's prior environment, and a production-grade prediction environment was deployed in minutes across protein, RNA, DNA, ligand, and antibody-antigen workloads drawn from the company's own discovery programs.
The deployment expands compute capacity beneath ReefIQ as MindWalk scales enterprise adoption following the platform's June 2026 launch; CEO Dr. Jennifer Bath said the standardized compute path shortens time from signing to first result and keeps costs from climbing with each partner added.
Red flags
- No disclosed contract, revenue, or financial terms; release itself flags the need to convert technical validation into contracted, recurring arrangements
- Results explicitly reflect specific configurations evaluated and 'are not representative of all workloads'
- Dependence on third-party compute providers (AMD GPUs, Vultr cloud) for cost, availability, and pricing of core infrastructure